<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631942</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.726</article-id><article-id pub-id-type="publisher-id">ofx163.726</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>A&#x000a0;Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maertens</surname><given-names>Johan</given-names></name><degrees>M.D, PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Schmitt</surname><given-names>Michael</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Marty</surname><given-names>Francisco M</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Ljungman</surname><given-names>Per</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Chemaly</surname><given-names>Roy F</given-names></name><degrees>MD, MPH, FIDSA, FACP</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Kartsonis</surname><given-names>Nicholas A</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Butterton</surname><given-names>Joan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Hong</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Teal</surname><given-names>Valerie L</given-names></name><degrees>M.S.</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Sarratt</surname><given-names>Kendra</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Murata</surname><given-names>Yoshihiko</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Leavitt</surname><given-names>Randi Y</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Badshah</surname><given-names>Cyrus</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Universitaire Ziekenhuizen Leuven</institution>, <addr-line>Leuven</addr-line>, <country>Belgium</country></aff><aff id="AF0002">
<label>2</label>
<institution>University of Heidelberg</institution>, <addr-line>Heidelberg</addr-line>, <country>Germany</country></aff><aff id="AF0003">
<label>3</label>
<institution>Dana-Farber Cancer Institute and Brigham and Women&#x02019;s Hospital</institution>, <addr-line>Boston, Massachusetts</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Karolinska University Hospital and Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><aff id="AF0005">
<label>5</label>
<institution>Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center</institution>, <addr-line>Houston, TX</addr-line></aff><aff id="AF0006">
<label>6</label>
<institution>Merck &#x00026; Co., Inc.</institution>, <addr-line>Kenilworth, New Jersey</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 139. Adult Viral Infection</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S311</fpage><lpage>S311</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.726.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>In a Phase III randomized, double-blind, placebo-controlled study of CMV-seropositive HCT recipients, letermovir prophylaxis significantly reduced the incidence of clinically significant CMV infections (CS-CMVi) through 24 weeks post-HCT. We investigated the impact of letermovir prophylaxis on mortality through Week 48 post-HCT.</p></sec><sec id="s2"><title>Methods</title><p>Adult CMV-seropositive allogeneic HCT recipients with undetectable plasma CMV DNA at screening who could initiate treatment by Week 4 post-HCT were eligible. Subjects stratified by high or low CMV disease risk were randomized 2:1 to letermovir dosed at 480&#x000a0;mg/d (240&#x000a0;mg/d if on cyclosporine) or placebo PO or IV through Week 14 post-HCT. Time to all-cause mortality and non-relapse mortality (defined as death due to any reason other than the indication for HCT) through Week 48 post-HCT are presented using Kaplan&#x02013;Meier (KM) plots censored at study discontinuation for reasons other than death/non-relapse death or upon study completion. Distribution of time to mortality endpoints was tested by stratified log-rank tests using two-sided <italic>P</italic>-values.</p></sec><sec id="s3"><title>Results</title><p>This analysis included all 565 patients randomized and treated with &#x02265;1 dose of study drug. Subjects began study drug a median of 9&#x000a0;days post-HCT; 36.5% started post-engraftment. The observed KM event rate for all-cause mortality was lower in the letermovir group (10.6%) than the placebo group (15.5%) at Week 24 post-HCT, and remained lower through Week 48 post-HCT (21.4% vs. 26.2%) (Figure&#x000a0;1). The observed K&#x02013;M event rate for all-cause mortality in subjects who developed CS-CMVi was also lower in the letermovir group (4.6%) than the placebo group (17.1%) at Week 48 post-HCT. The observed KM event rate for non-relapse mortality was lower in the letermovir group (6.9%) vs. the placebo group (11.2%) at Week 24 post-HCT, and remained lower in the letermovir group (13.9%) than the placebo group (17.5%) through Week 48 post-HCT (Figure&#x000a0;2).</p></sec><sec id="s4"><title>Conclusion</title><p>All-cause and non-relapse mortality were reduced in the letermovir group compared with the placebo group through Week 48 post-HCT (relative risk reduction ~18% and ~21%, respectively). These results are consistent with a clinically meaningful survival benefit for letermovir prophylaxis.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0300"/></fig></sec><sec id="s5"><title>Disclosures</title><p>
<bold>J.&#x000a0;Maertens</bold>, MSD: Consultant and Investigator, Consulting fee, Research grant and Speaker honorarium. <bold>M. Schmitt</bold>, MSD: Consultant and Investigator, Consulting fee. <bold>F. M.&#x000a0;Marty</bold>, Merck &#x00026; Co., Inc.: Consultant, Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient. <bold>P. Ljungman</bold>, Merck &#x00026; Co., Inc.: Consultant and Investigator, Consulting fee, Research grant and Speaker honorarium. <bold>R. F.&#x000a0;Chemaly</bold>, Merck &#x00026; Co., Inc.: Consultant and Investigator, Consulting fee, Research grant and Speaker honorarium. <bold>N. A.&#x000a0;Kartsonis</bold>, Merck &#x00026; Co., Inc.: Employee, Salary and stock/stock options. <bold>J. Butterton</bold>, Merck &#x00026; Co., Inc.: Employee, Salary and stock, stock options. <bold>H. Wan</bold>, Merck &#x00026; Co., Inc.: Employee, Salary and stock, stock options.<bold>V. L.&#x000a0;Teal</bold>, Merck &#x00026; Co., Inc.: Employee, Salary and Stock/stock options. <bold>K. Sarratt</bold>, Merck &#x00026; Co., Inc.: Employee, Salary and stock &#x00026; stock options. <bold>Y. Murata</bold>, Merck &#x00026; Co., Inc.: Employee, Salary and stock and stock options. <bold>R. Y.&#x000a0;Leavitt</bold>, Merck &#x00026; Co., Inc.: Employee, Salary and stock, stock options. <bold>C. Badshah</bold>, Merck &#x00026; Co., Inc.: Employee, Salary and stock, stock options</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>